Skip to main content
SpringerLink
Log in

One third of MRSA drug market dominated by Teflaro and tedizolid

  • Media release
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Rights and permissions

Reprints and permissions

About this article

Cite this article

One third of MRSA drug market dominated by Teflaro and tedizolid. Pharmacoecon. Outcomes News 644, 11 (2012). https://doi.org/10.2165/00151234-201206440-00031

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00151234-201206440-00031

Keywords

Search

Navigation